About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
  Corporate Structure
  Corporate Governance
  Company History
  Annual General Meeting
  Postal Ballot
  Investor FAQs
  Stock Info
  Financial Results
  Subsidiary Financials
  Annual Report
  Disclosure to Stock Exchange
  Nomination form
  Press Releases
  Analyst Coverage
  Investor Contacts
  FY 2016 - 2017
  April 2017
  March 2017
  February 2017
  January 2017
  December 2016
  November 2016
  October 2016
  September 2016
  August 2016
  July 2016
  June 2016
  May 2016
  April 2016
Disclosure to Stock Exchange

  July 2016
28 July  Biocon Initiates "Ek Prayaas" Nationwide  Awareness Program on Hepatitis C Download Pdf
21 July  Biocon Reports a Strong Q1FY17
 Revenues at Rs 952 Crore, up by 11 %;  EBITDA Up 15% to Rs 271 Crore
 Net Profit Up 17% at Rs 147 Crore
Download Pdf
21 July  Mylan & Biocon Announce Regulatory  Submission for Proposed Biosimilar  Pegfilgrastim Accepted for Review by  European Medicines Agency Download Pdf
15 July  Biocon's Insulin Glargine Launched in Japan Download Pdf

 March 2016
 February 2016
 January 2016
 December 2015


Recommended sites Biocon on  
About Us

Investor Relations
Media Relations
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Research Services
Active Discovery Program

Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
  Report adverse event/side effects and product complaints    
  * Disclaimer            © 2018, Biocon. All Rights Reserved